UBS Group started coverage on shares of Bruker (NASDAQ:BRKR) in a research note released on Tuesday, 99wallstreet.com reports. The brokerage issued a sell rating and a $30.00 price target on the medical research company’s stock. The analysts noted that the move was a valuation call.
BRKR has been the topic of a number of other reports. Morgan Stanley cut their price target on shares of Bruker from $31.00 to $29.00 and set an equal weight rating on the stock in a report on Friday, July 13th. Zacks Investment Research downgraded shares of Bruker from a hold rating to a sell rating in a report on Tuesday, July 24th. BidaskClub raised shares of Bruker from a hold rating to a buy rating in a report on Friday, August 24th. Finally, ValuEngine raised shares of Bruker from a hold rating to a buy rating in a report on Wednesday, August 8th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $33.90.
Shares of NASDAQ:BRKR opened at $31.42 on Tuesday. The company has a current ratio of 2.22, a quick ratio of 1.27 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $5.23 billion, a P/E ratio of 25.82, a P/E/G ratio of 2.11 and a beta of 1.34. Bruker has a fifty-two week low of $28.13 and a fifty-two week high of $36.53.
Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, August 2nd. The medical research company reported $0.25 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.25. The company had revenue of $443.70 million for the quarter, compared to the consensus estimate of $436.10 million. Bruker had a net margin of 4.99% and a return on equity of 27.03%. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.23 EPS. On average, analysts expect that Bruker will post 1.38 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 21st. Investors of record on Tuesday, September 4th were paid a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.51%. The ex-dividend date was Friday, August 31st. Bruker’s dividend payout ratio is currently 13.22%.
Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in Bruker in the 2nd quarter valued at about $101,000. Sun Life Financial INC bought a new stake in Bruker in the 2nd quarter valued at about $163,000. TLP Group LLC bought a new stake in Bruker in the 1st quarter valued at about $190,000. Strs Ohio bought a new stake in Bruker in the 2nd quarter valued at about $327,000. Finally, State of Alaska Department of Revenue raised its stake in Bruker by 35.6% in the 2nd quarter. State of Alaska Department of Revenue now owns 11,510 shares of the medical research company’s stock valued at $334,000 after acquiring an additional 3,020 shares during the period. Institutional investors and hedge funds own 65.61% of the company’s stock.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Read More: What is the yield curve?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.